SCLC
Clinical trials for SCLC explained in plain language.
Never miss a new study
Get alerted when new SCLC trials appear
Sign up with your email to follow new studies for SCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough cancers: first human test of experimental drug begins
Disease control Recruiting nowThis is an early-stage study to test the safety and find the right dose of a new experimental drug, JAB-8263, in adults with advanced cancers that have not responded to standard treatments. The trial will enroll about 152 people with various advanced solid tumors (like lung or ov…
Matched conditions: SCLC
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
First-of-its-Kind pill targets Cancer's 'Guardian Gene' mutation
Disease control Recruiting nowThis study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…
Matched conditions: SCLC
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Real-World check on promising lung cancer drug
Disease control Recruiting nowThis study aims to see how well the drug Zepzelca works and how safe it is for patients with advanced small cell lung cancer in everyday medical practice. It will observe about 300 patients whose cancer has spread and who have already tried standard chemotherapy. The main goal is…
Matched conditions: SCLC
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for cancers that resist standard treatments
Disease control Recruiting nowThis study is testing whether combining two drugs can help people with aggressive cancers that have stopped responding to standard treatments. It focuses on small cell lung cancer and other cancers with specific genetic weaknesses that have become resistant to previous drugs. The…
Matched conditions: SCLC
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug combo tested to keep aggressive lung cancer at bay
Disease control Recruiting nowThis study is testing whether adding a new drug called golidocitinib to standard immunotherapy (PD-1 inhibitors) can help control extensive-stage small cell lung cancer for longer. After initial chemotherapy, participants receive the two-drug combination as maintenance therapy to…
Matched conditions: SCLC
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New cancer drug trial seeks to control advanced tumors
Disease control Recruiting nowThis study is testing a new drug called TUB-030 in adults with advanced solid cancers that have not responded to other treatments. The main goals are to find the safest dose and see if the drug helps control the cancer. It will focus on specific cancers like head and neck cancer …
Matched conditions: SCLC
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New radiation approach aims to protect brain cancer patients from treatment side effects
Disease control Recruiting nowThis study compares two radiation methods for patients whose cancer has spread to the brain and who are receiving immunotherapy. Researchers want to see if giving smaller radiation doses over several days causes fewer side effects than the standard single-day treatment. The trial…
Matched conditions: SCLC
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New hope drug enters human testing for ten types of advanced cancer
Disease control Recruiting nowThis is the first human study of an experimental drug called SLV-154 for people with advanced solid tumors that have spread. The main goal is to find the highest safe dose and understand how the body processes the drug. About 70 adults with one of ten specific advanced cancers wh…
Matched conditions: SCLC
Phase: PHASE1 • Sponsor: Solve Therapeutics • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC